TrialEuropean journal of heart failure2017

A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.

Cristina Tita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.